Support: (+84) 28 7308 5885 - (Ext) 303 or 310

POSEIDON groups and their distinct reproductive outcomes: Effectiveness and cost-effectiveness insights from real-world data research

Sandro C.Estevesab, HakanYaralic, Lan N.Vuongdef, AlessandroConfortig, PeterHumaidanbh, CarloAlviggig

Published: December, 2022

a Andrology and Human Reproduction Clinic, Av. Dr. Heitor Penteado, 1464, Campinas, Brazil
b Faculty of Health, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
c Anatolia IVF and Department of Obstetrics and Gynecology, Hacettepe University, Ankara, Turkey
d Department of Obstetrics and Gynecology, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam
e IVFMD, My Duc Hospital, Ho Chi Minh City, Viet Nam
HOPE Research Center, My Duc Hospital, Ho Chi Minh City, Viet Nam
g Department of Neuroscience, Reproductive Science and Odontostomatology, University of Naples, Federico II, Naples, Italy
h Fertility Clinic Skive, Skive Regional Hospital, Skive & Aarhus University, Aarhus, Denmark


The Patient Oriented Strategies Encompassing IndividualizeD Oocyte Number (POSEIDON) criteria identify and classify the so-called ‘low-prognosis’ patients undergoing assisted reproductive technology (ART). Recent large-scale studies using real-world data (RWD) have shown that patients classified under this system have distinct reproductive outcomes. Moreover, these studies also confirm that POSEIDON patients are commonly found in fertility centers. RWD has substantiated the validity of the POSEIDON biomarkers’ thresholds (antral follicle count [AFC] and/or anti-Müllerian hormone [AMH]) for patient classification. Lastly, a predictive model has been developed and validated to estimate the POSEIDON metric of success (i.e., number of oocytes needed to achieve at least one euploid blastocyst). Although more evidence is needed in this area, current insights from RWD research indicate that infertility patients can be counseled and managed more effectively under the POSEIDON scope, with potential gains for all parties involved.


Assisted reproductive technology, Infertility, ART calculator, Cumulative delivery rate, POSEIDON criteria, Real-word data